Introduction Executive Summary Interleukin-33 inhibitors: Overview • Structure • Mechanism of Action Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Interleukin-33 inhibitors – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Interleukin-33 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends Interleukin-33 inhibitors Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis Itepekimab: Regeneron Pharmaceuticals/Sanofi • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis MEDI3506: AstraZeneca • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Early Stage Products (Phase I) • Comparative Analysis Drug name: Company name • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products • Comparative Analysis CAN-10: Cantargia • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Interleukin-33 inhibitors Key Companies Interleukin-33 inhibitors Key Products Interleukin-33 inhibitors- Unmet Needs Interleukin-33 inhibitors- Market Drivers and Barriers Interleukin-33 inhibitors- Future Perspectives and Conclusion Interleukin-33 inhibitors Analyst Views Interleukin-33 inhibitors Key Companies Appendix

Table 1 Total Products for Interleukin-33 inhibitors Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• AstraZeneca • Regeneron Pharmaceuticals • Sanofi • Genentech • Cantargia